CLAIM CARDS
Claim Cards
Atomic claims extracted from accepted Researka artifacts, with source support, contradiction state, and provenance links when available.
Filtered to publication 8b15f6df-c45d-4575-89cb-441c5de831bd
exploratory
Headline:** Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy
Contradiction: none
Sources: 5
exploratoryThe cited A/B receipts support a specific working claim: reduced risk associated with acarbose was only observed... in non-users of metformin (adjusted hazard ratio, 0.635; 95% confidence interval, 0.481-0.837); users of all three drugs had the lowest risk of dementia (hazard ratio, 0.406; 95% confidence interval, 0.178-0.925). The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.
Contradiction: none
Sources: 5
exploratoryInterpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.
Contradiction: none
Sources: 5
exploratoryThe discordance between acarbose's pronounced male-specific lifespan extension in genetically heterogeneous mice and its female-preferential dementia risk reduction in human type 2 diabetes patients suggests that sex-hormone interactions or differential gut-brain axis modulation may underpin its geroprotective effects, inviting mechanistic studies beyond glucose lowering.
Contradiction: none
Sources: 5
exploratoryReal tension: Acarbose increased median lifespan by 22% in male mice but only 5% in female mice (facts 3,4), whereas in human T2D patients, it reduced dementia risk only in women with an HR of 0.783 (fact 12).
Contradiction: none
Sources: 5
exploratory`fact_id=187300` (`A_core`) — reduced risk associated with acarbose was only observed... in non-users of metformin (adjusted hazard ratio, 0.635; 95% confidence interval, 0.481-0.837) doi=10.14336/ad.2019.0621
Contradiction: none
Sources: 5
exploratory`fact_id=187299` (`A_core`) — users of all three drugs had the lowest risk of dementia (hazard ratio, 0.406; 95% confidence interval, 0.178-0.925) doi=10.14336/ad.2019.0621
Contradiction: none
Sources: 5
exploratory`fact_id=135514` (`A_core`) — The mean HbA1c at week 24 was significantly decreased approximately 0.7% from baseline in both acarbose and voglibose groups. doi=10.3346/jkms.2014.29.1.90
Contradiction: none
Sources: 5
exploratory`fact_id=70369` (`A_core`) — Acarbose increased male median lifespan by 22% (P < 0.0001) doi=10.1111/acel.12170
Contradiction: none
Sources: 5
exploratory`fact_id=135510` (`A_core`) — acarbose produced 51% decrease in maltose loaded diabetic rats doi=10.4236/jdm.2012.21013
Contradiction: none
Sources: 5
exploratory`fact_id=108410` (`A_core`) — significantly increased (3%) in females only at 1,000 ppm doi=10.1111/acel.12898
Contradiction: none
Sources: 5
exploratory_No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._
Contradiction: none
Sources: 5
exploratorySuggested citation:** Dom Lynch. (2026). Polypharmacy Strategies with Acarbose for Dementia Risk Reduction in Type 2 Diabetes: Evidence from Subgroup Analyses and Combination Therapy. ReseaRka Evidence Index. Version 1.0.
Contradiction: none
Sources: 5
exploratoryPriority note:** This memo records the first published framing, source bundle, and evidence receipts for this run. Reuse should cite the canonical version.
Contradiction: none
Sources: 5